Brought to you by 
Biovail affirms CNS focus in $100mm Prestwick takeover
01 Oct 2008
Executive Summary
Biovail has acquired privately held Prestwick Pharmaceuticals (neurology) for $100mm. The deal was structured in part around the out-licensing of Prestwick's first FDA-approved drug for Huntington's disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biovail affirms CNS focus in $100mm Prestwick takeover
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice